Ranbaxy Launches Generic Clarithromycin After Defeating Abbott In U.K. Court

Law360, New York (December 1, 2004, 12:00 AM EST) -- Indian drug maker Ranbaxy Laboratories Ltd. has a launched a generic version of the anti-infective drug clarithromycin in the U.K. after winning a patent infringement lawsuit brought by U.S.-based Abbott Laboratories.

Abbott had taken the Indian generic maker to court seeking to prevent Ranbaxy from launching the drug, but the High Court sided with Ranbaxy.

“In making its ruling in favor of Ranbaxy's arguments that the asserted patent was invalid on various grounds, the court agreed that the specific patent claims asserted by Abbott were invalid...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.